Suxibuzone

Suxibuzone

Suxibuzone is a non-steroidal anti-inflammatory drug (NSAID) that is primarily used in veterinary medicine for the treatment of pain and inflammation associated with musculoskeletal conditions in horses. It is a prodrug of phenylbutazone, which means it is metabolized in the body to produce the active drug.

Pharmacology

Suxibuzone is a prodrug of phenylbutazone, which is a non-selective inhibitor of the enzyme cyclooxygenase (COX). This enzyme is involved in the production of prostaglandins, which are chemicals that promote inflammation, pain, and fever. By inhibiting COX, suxibuzone reduces the production of these chemicals, thereby reducing inflammation and pain.

Uses

Suxibuzone is primarily used in horses for the alleviation of inflammation and pain associated with musculoskeletal disorders. It is also used for the relief of colic pain in horses. It is not approved for use in humans or any other animals.

Side Effects

As with other NSAIDs, suxibuzone can cause side effects such as gastrointestinal ulcers, kidney damage, and blood dyscrasias. These side effects are more likely to occur with long-term use or at high doses.

Regulation

In the United States, suxibuzone is classified as a prescription drug and can only be used under the supervision of a licensed veterinarian. It is not approved for use in horses intended for food.

See Also

• Phenylbutazone
• Non-steroidal anti-inflammatory drug
• Prodrug
• Cyclooxygenase
• Prostaglandin

‎